# Verve Therapeutics

prime editing moving in vivo via all-RNA LNP platforms, and Verve's VERVE-102 (now under Eli Lilly) cutting LDL-C by up to 62% from a single PCSK9 base edit.

Source: https://en.bioecon.ru/companies/verve-therapeutics/
Updated: 2026-06-24

- Country: United States
- Ticker: VERV

## Technologies

- [Genome editing](https://en.bioecon.ru/technology/genome-editing/)